1. Home
  2. JPC vs MESO Comparison

JPC vs MESO Comparison

Compare JPC & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Preferred & Income Opportunities Fund

JPC

Nuveen Preferred & Income Opportunities Fund

HOLD

Current Price

$7.92

Market Cap

2.8B

Sector

Finance

ML Signal

HOLD

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$15.75

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JPC
MESO
Founded
N/A
2004
Country
United States
Australia
Employees
N/A
81
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
2.2B
IPO Year
2003
N/A

Fundamental Metrics

Financial Performance
Metric
JPC
MESO
Price
$7.92
$15.75
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
1.4M
269.4K
Earning Date
01-01-0001
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$644.56
Revenue Next Year
N/A
$38.63
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.22
$9.88
52 Week High
$8.30
$21.50

Technical Indicators

Market Signals
Indicator
JPC
MESO
Relative Strength Index (RSI) 53.21 55.52
Support Level $7.22 $15.62
Resistance Level $8.21 $16.77
Average True Range (ATR) 0.16 0.56
MACD 0.05 0.14
Stochastic Oscillator 95.27 76.56

Price Performance

Historical Comparison
JPC
MESO

About JPC Nuveen Preferred & Income Opportunities Fund

Nuveen Preferred & Income Opportunities Fund is a diversified closed-end management investment company. Its primary investment objective is to provide high current income, and its secondary investment objective is total return. The fund invests a majority of its assets in preferred securities and other income-producing securities, including hybrid securities such as contingent capital securities, and the rest of its investments are made in other securities, mainly income-oriented securities such as corporate and taxable municipal debt and common equity.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: